Adeptrix Corp
Boston, MA
- UEI
- UD9UKVEQNV49
- CAGE
- 66QV9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 71 Church St #6, Boston, MA 02122, USA
- Website
- adeptrix.com
- Founded
- 2012
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Adeptrix Corp is a biotechnology company based in Boston, Massachusetts, specializing in advanced immunoassay and mass spectrometry technologies for medical research and diagnostic applications. Registered in SAM.gov since 2010, the company is structured as a for-profit corporate entity and is self-certified as a small disadvantaged business. Adeptrix focuses on developing innovative molecular profiling and detection platforms that enable highly sensitive analysis of complex protein biomarkers, with a particular emphasis on neurodegenerative disease research and diagnostic technologies.
The company has received multiple federal grants from agencies like the National Institute on Aging and National Cancer Institute, focusing on developing sophisticated multiplexed immunoassay technologies for detecting and quantifying protein biomarkers. Their recent grant projects include TAUTRACE, an ultrasensitive immunoassay for detecting Alzheimer's disease tau protein biomarkers, PATH10, a multiplexed protein-based multi-pathway profiling assay, and HistoneScan, a multiplex analytical assay for detecting histone protein modifications. Adeptrix has also engaged in COVID-19 related research through sub-awards from The General Hospital Corporation, developing analytical assays for detecting SARS-CoV-2 viral strains and sequence variants using immunoaffinity-peptide mass fingerprinting technology. Their grant work demonstrates a strong capability in developing advanced diagnostic and research tools that leverage sophisticated immunoassay and mass spectrometry techniques across multiple scientific domains, with a particular focus on neuroscience, cancer research, and virology.
Quick answers
Is Adeptrix Corp registered in SAM.gov?
Yes. Adeptrix Corp's SAM.gov registration is active through December 15, 2026.
What is Adeptrix Corp's most recent federal award?
Adeptrix Corp's most recent federal grant award is Tautrace™: an ultrasensitive immunoassay for neurodegenerative protein biomarkers (R43AG094422), from National Institute on Aging (NIH), on September 11, 2025.
On GovTribe
See Adeptrix Corp's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors